©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 1084-1090
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.1084
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.1084
Hemorrhagic cystitis in gastric cancer after nanoparticle albumin-bound paclitaxel: A case report
Xin-Jie Zhang, Jian Lou, Department of Cancer Center, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang Province, China
Author contributions: Zhang XJ collected data and drafted the manuscript; Lou J revised and finalized the manuscript; all authors have read and approved the final manuscript.
Informed consent statement: Written informed consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Jian Lou, MM, Chief Physician, Department of Cancer Center, The Fifth Affiliated Hospital of Wenzhou Medical University, No. 289 Kuocang Road, Liandu District, Lishui 323000, Zhejiang Province, China. 19994454@qq.com
Received: December 24, 2023
Peer-review started: December 24, 2023
First decision: January 10, 2024
Revised: January 18, 2024
Accepted: January 27, 2024
Article in press: January 27, 2024
Published online: March 15, 2024
Processing time: 78 Days and 18.6 Hours
Peer-review started: December 24, 2023
First decision: January 10, 2024
Revised: January 18, 2024
Accepted: January 27, 2024
Article in press: January 27, 2024
Published online: March 15, 2024
Processing time: 78 Days and 18.6 Hours
Core Tip
Core Tip: Chemotherapy is an important treatment method for advanced gastric cancer. Up to now, nanoparticle albumin-bound paclitaxel (Nab-PTX) has shown promising responses in advanced gastric cancer. We aim to draw attention to a rarely treatment-related adverse event after Nab-PTX.